University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital, Dallas
University of Texas Southwestern Medical Center-Zale Lipshy University Hospital, Dallas
at 3 pa

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06989437

A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

NEXT Oncology, Austin
NEXT Oncology, Dallas
SCRI at Mary Crowley, Dallas
at 3 pa

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07612176

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, Dallas
Research Site, El Paso
Research Site, Sugar Land

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

University of Texas Southwestern Medical Center, Dallas
Houston Methodist Cancer Center, Houston
The University of Texas M.D. Anderson Cancer Center, Houston

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07007559

Intratumoral N17350 in Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07339176

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

USO-Texas Oncology-Central/South Texas, Austin
World Research Link, Baytown
Parkland Health and Hospital System, Dallas
at 5 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07218380

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Oncology Consultants, P.A., Houston

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07028489

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Hendrick Medical Center, Abilene
World Research Link, Baytown
Parkland Health and Hospital System, Dallas
at 10 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07174336

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

MD Anderson, Houston
NEXT Dallas, Irving
NEXT Oncology San Antonio, San Antonio
at 1 pa

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06128551

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Texas Oncology - DFW (Sammons CC), Dallas
MD Anderson Cancer Center, Houston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07114601

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

START Dallas Fort Worth, Fort Worth
University of Texas MD Anderson Cancer Center, Houston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07262619

SLV-154 Treatment of Advanced Cancers

MD Anderson Cancer Center, Houston
Oncology Consultants, Houston
Mays Cancer Center; University of Texas Health San Antonio, San Antonio

Nagre-recruitPhase 1

Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06771219

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

USO-Texas Oncology-Central/South Texas, Austin
UT Southwestern Medical Center, Dallas
US Oncology, The Woodlands
at 1 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07213804

A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

NEXT Houston, Houston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07693751

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Next Oncology - Dallas, Irving

Nagre-recruitPhase 1

Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07403721

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07629960

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

M D Anderson Cancer Center, Houston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT04693468

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Texas Oncology (Balcones) - SCRI, Austin
MD Anderson Cancer Center, Houston
START South Texas Accelerated Research Therapeutics, San Antonio

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05267626

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Texas Oncology - Central South, Austin
Texas Oncology - Central South, Austin
Texas Oncology - Central South, Austin
at 26 pa

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07227415

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.